Providing Critical Data in Early Clinical Development with Scintigraphy

Clinical Trials, Drug Discovery & Development, Life Sciences,
  • Thursday, March 28, 2019 | 9am EDT (NA) / 1pm GMT (UK) / 2pm CET (EU-Central)
  • 60 min

If you are embarking on your clinical development plan, consider a non-invasive in vivo evaluation of drug delivery systems. Scintigraphy gives you the power to study drugs in gastrointestinal organs, providing you with valuable data earlier on in the drug development process.

In this live webinar, our featured speakers will cover:

  • The benefits of scintigraphy in early phase research
  • Drug delivery routes, including oral, pulmonary, and nasal
  • Residence of drug delivery systems at the site of action/absorption
  • Overview of scintigraphy as a fully quantifiable and trial-validated procedure
  • Review of radiolabelling procedures and radiolabelling validation
  • The importance of a multi-disciplined team required to operationalise the study

Speakers

Professor Glyn Taylor, Research Director, Cardiff Scintigraphics Limited (CSL)

Professor Glyn Taylor holds a BSc in Pharmacy and a PhD in Pharmacokinetics. He joined the Welsh School of Pharmacy in 1980 and later was a research fellow at Stanford University (1982-83) and then a visiting assistant professor at the University of California, San Francisco (1989-90). He was Professor of Drug Delivery at Cardiff Unversity until 2015.

In 1992, Professor Taylor co-founded CSL, a company which provides clinical and in vitro evaluation of pharmaceuticals and drug delivery systems using techniques including gamma scintigraphy.   CSL has performed scintigraphy studies for many niche device and global pharma companies. In 2012, CSL was shortlisted for the Queen’s Award for Enterprise (Innovation).

Message Presenter

Dr. Christopher Jeans, CMC Consultant and Qualified Person, Simbec-Orion

Dr. Christopher Jeans joined Simbec-Orion as a research pharmacist in 2007 following experience in academic, hospital and community pharmacy. He attained QP eligibility in 2013. He is responsible for certifying that batches of IMP have been manufactured in accordance with EU GMP and the Clinical Trial Authorisation, as per the requirement of the Clinical Trials Directive. Dr. Jeans offers advice and consultancy to Simbec-Orion clients on CMC and GMP activities.

Message Presenter

Who Should Attend?

This webinar will appeal to small and mid-size drug developers in Europe and the US focused on translational medicine and clinical pharmacology.

Key job titles include:

  • CEO
  • CSO
  • VP/Director Clinical Operations
  • VP/Director Clinical Programme Management
  • VP/Director R&D

What You Will Learn

In this webinar, participants will explore:

  • The benefits of scintigraphy in early phase research
  • Drug delivery routes, including oral, pulmonary, and nasal
  • Residence of drug delivery systems at the site of action/absorption
  • Overview of scintigraphy as a fully quantifiable and trial-validated procedure
  • Review of radiolabelling procedures and radiolabelling validation
  • The importance of a multi-disciplined team required to operationalise the study

Xtalks Partner

Simbec-Orion

Simbec-Orion Group is a full-service Boutique international CRO. Focused on oncology, rare disease and healthy volunteer studies.  We offer our clients a full spectrum of drug development services from first-in-human Phase I clinical studies through to pivotal Phase III studies and Phase IV post-marketing studies. We have expertise in all drug types, dosage forms and delivery mechanisms. Established in 1976 our experience and expertise enables us to become a true ally on your drug development journey.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account